NCT03123276View on ClinicalTrials.gov

Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

May 20, 2022

Study Completion Date

May 20, 2022

Conditions
Sarcoma
Interventions
DRUG

Pembrolizumab

humanized IgG4 PD-1 blocking antibody

DRUG

Gemcitabine

Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.

Trial Locations (1)

Unknown

Royal Marsden, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT03123276 - Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma | Biotech Hunter | Biotech Hunter